Associate Professor of Medicine
Member of the Duke Cancer Institute
Email address
michael.harrison@duke.edu
Education and Training
- residency, Medicine, Tulane University, 2004 - 2007
- M.D., Tulane University, 2004
Grants
- ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
- A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unr
- Phase II Single Arm Study of Gemcitabine and Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer
- Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects
- A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcin
- Ipilimumab and Nivolumab Combination Therapy: A Randomized Study of an Immediate versus Delayed Exercise Intervention with FuNctional Capacity and Quality of Life Evaluations in Subjects with Advanced
- Cardiopulmonary Exercise Testing (CPET) in Patients Treated with Schedule 2/1 and 4/2 for Metastic Renal Cell Carcinoma: A Randomized Multi-Site Trial
- Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual Checkpoint Inhibition in Platinum Resistant Metastatic Urothelial Carcinoma
- A Phase III, open-label, multi-center, randomized study to investigate the efficacy and safety of MPDL3280A
- True NTH Project
- True NTH Project: Self-Management Portal & Decision Support
- A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus
- EXTEND PC: Safety and Efficacy of Exercise Training in Men Receiving Enzalutamide in Cominbation iwth Conventional Andr
- Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Metastatic Renal Cell Cancer Registry (MaRCC Registry)